Skip to main content
Premium Trial:

Request an Annual Quote

Caliper's Q1 Revenues, Net Loss Increase 3 Percent

NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported that its first-quarter revenues rose 3 percent but were flat when excluding favorable foreign currency effects. The firm’s net loss also rose 3.1 percent year over year.
 
Caliper brought in revenues of $29.3 million for the three-month period ended March 31, compared to $28.4 million for the first quarter of 2007. Product revenues rose to $17.7 million from $15.3 million, while service revenues increased to $9 million from $8.9 million, and licensing fees and contract revenues dropped sharply to $2.6 million from $4.2 million.
 
The decline in licensing revenue was anticipated, according to Caliper President and CEO Kevin Hrusovsky, and was related to microfluidic licensing revenue in 2007 that was not repeated in the first quarter of 2008.
 
The Hopkinton, Mass.-based company posted a net loss of $9.9 million, or $.21 per share, compared to a net loss of $9.6 million, or $.20 per share, for Q1 2007.
 
Caliper’s R&D expenses declined 19.1 percent to $5.5 million from $6.8 million, while its SG&A costs increased 10.3 percent to $13.9 million from $12.6 million.
 
Caliper finished the quarter with $13.6 million in cash and cash equivalents.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.